Cara Therapeutics Inc CARA shares are trading higher by 54 cents (4.2 percent) at $13.00 in Monday's session.
Before the open, the company said it had received "productive" guidance from the FDA from its Phase 2 meeting for I.V. CR485, which may support a new drug application.
After a $1 higher open, Cara went only another 7 cents before peaking at $13.58 and reversed course. That high coincides with a pair of highs from last Wednesday ($13.62) and Thursday ($13.64). Profit-takes then came into the stock, nudging it in the top of Friday's range ($13.05), as $12.90 stands as the low for the session as of 11:35 a.m. EST.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.